The swing tags the stock as one of the day's most volatile. Analysts forecast that Insys Therapeutics will post ($0.29) EPS for the current fiscal year. Alpha One also assigned news coverage about the specialty pharmaceutical company an impact score of 89 out of 100, meaning that recent media coverage is very likely to have an effect on the company's share price in the near term. 668,411 shares of the company's stock traded hands.
The $7.55 is the stock's low for the year. Shares of the company are trading at $7.84 impressively lower than $9.20, the stock's 50 day moving average and which is significantly lower than the 200 day moving average of $10.99. The firm's market capitalization is $570.66 million.
Several other equities research analysts have also issued reports on INSY. The specialty pharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.12. Insys Therapeutics had a net margin of 8.71% and a return on equity of 9.39%. The business had revenue of $42.60 million during the quarter, compared to analyst estimates of $36.90 million. The drug makes up approximately 98 percent of Insys' revenues.
A number of research firms recently weighed in on INSY. BidaskClub lowered shares of Insys Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 5th. Royal Bank of Canada reaffirmed a "buy" rating and set a $16.00 price objective on shares of Insys Therapeutics in a research report on Friday, April 28th. Oppenheimer Holdings, Inc. reiterated a "hold" rating on shares of Insys Therapeutics in a research report on Thursday, August 3rd. One analyst rating the company a strong buy, three analysts rating the company a buy, one analyst rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a one year target of $24.40. The company presently has an average rating of "Hold" and a consensus target price of $13.25. The stock was acquired at an average cost of $12.21 per share, for a total transaction of $97,680.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. The stock was purchased at an average price of $11.98 per share, with a total value of $53,910.00. American International Group Inc. now owns 14,462 shares of the specialty pharmaceutical company's stock worth $152,000 after buying an additional 953 shares during the period. The disclosure for this purchase can be found here.